Avacta to Present at Virtual Theranostics FAP Summit

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that it will be presenting at the Theranostics FAP Summit, organised by the International Centers for Precision Oncology Foundation, being held on 5 November 2022.

The online meeting will feature world-renowned experts in the biology of Fibroblast Activation Protein (FAP), which is highly expressed in cancer-associated fibroblasts (CAF) across many tumour types. Representatives from academia and industry will take a deep dive into the topic of FAP, its history and role in the biology of disease, the current state of research, and future applications in both diagnostics and therapeutic areas.

AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using Avacta’s pre|CISION technology so that it is activated by FAP, predominantly in the tumour, with the aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficacy of the drug. Avacta’s presentation, to be given by Dr Fiona Maclaughlin, Chief Scientific Officer of the Therapeutics division, will highlight the pre-clinical development of AVA6000.

No new information will be shared as part of the presentation.

Title: Pre-clinical Development of AVA6000 – a FAP targeted chemotherapeutic agent in Phase I

Day/Date: Saturday, 5 November 2022

Time: 17:30 – 17:45 CET

Session number: VI